Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | MC5R | P33032 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16047096 | 0.89 | CASR (0.50) | CASRTNFNOD1ALDH1A1TDP1 | |
| SCHEMBL227210 | 0.88 | CASR (0.58) | CASRTNFNOD1ALDH1A1TDP1 | |
| SCHEMBL7544923 | 0.84 | CASR (0.64) | CASRTNFNOD1ALDH1A1TDP1 | |
| SCHEMBL24496148 | 0.81 | CASR (0.53) | CASRTNFNOD1ALDH1A1TDP1 | |
| SCHEMBL21706357 | 0.81 | CASR (0.53) | CASRTNFNOD1FBP1 | |
| SCHEMBL12545796 | 0.81 | CASR (0.53) | CASRTNFNOD1FBP1L3MBTL1 | |
| SCHEMBL5720317 | 0.81 | CASR (0.51) | CASRALDH1A1TDP1ADRA2AFBP1 | |
| SCHEMBL9052764 | 0.80 | CASR (0.51) | CASRTNFNOD1ALDH1A1TDP1 | |
| SCHEMBL9037002 | 0.80 | THRB (0.51) | CASRTNFNOD1ALDH1A1TDP1 | |
| SCHEMBL1417435 | 0.80 | CASR (0.51) | CASRTNFNOD1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110317374-A | A kind of special vehicle solid wheel rubber material and preparation method thereof based on modified chopped carbon fiber | 青岛科技大学 | 2019-10-11 | — | — | CN | claimed |
| JP-61186372-A | — | — | None | — | — | JP | disclosed |
| CN-119144088-A | Rubber processing modified masterbatch, vulcanized rubber, preparation methods thereof and application of rubber processing modified masterbatch and vulcanized rubber in tire tread | 中国石油化工股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119144076-A | Rubber processing modified master batch, preparation method and application thereof, rubber composition and application thereof, vulcanized rubber and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119144111-A | Rubber processing modified masterbatch and vulcanized rubber for tire tread, and preparation methods and applications thereof | 中国石油化工股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070015143-A1 | PREPARATION AND USE OF MIXED MODE SOLID SUBSTRATES FOR CHROMATOGRAPHY ADSORBENTS AND BIOCHIP ARRAYS | PALL CORPORATION (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| EP-1572798-A1 | RUBBER COMPOSITIONS AND ARTICLES THEREOF HAVING IMPROVED METAL ADHESION AND METAL ADHESION RETENTION WITH BRIGHT STEEL | Bridgestone/Firestone North American Tire, LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050119383-A1 | Rubber compositions and articles thereof having improved metal adhesion and metal adhesion retention with bright steel | BRIDGESTONE/FIRESTONE NORTH AMERICAN TIRE, LLC | 2005-06-02 | — | — | US | disclosed |
| WO-2004058871-A1 | RUBBER COMPOSITIONS AND ARTICLES THEREOF HAVING IMPROVED METAL ADHESION AND METAL ADHESION RETENTION WITH BRIGHT STEEL | BRIDGESTONE/FIRESTONE NORTH AMERICAN TIRE, LLC (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| JP-S61186372-A | PRODUCTION OF BENZOTHIAZOLE | AGENCY OF IND SCIENCE & TECHNOL | 1986-08-20 | — | — | JP | disclosed |
| US-4259403-A | ACID OR ANHYDRIDE OF VICINAL DI-ACID | UNIROYAL, INC. (US) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CASR 1743/4885TNF 4203/4885NOD1 4454/4885 |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | CASR 3409/4885TNF 4047/4885NOD1 3467/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | CASR 883/4885TNF 4625/4885NOD1 3402/4885 |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | CASR 3737/4885TNF 132/4885NOD1 423/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | CASR 974/4885TNF 1058/4885NOD1 3777/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | CASR 2429/4885TNF 352/4885NOD1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.